Seven questions, 60-second thesis frame.

What changed, and when

Chiesi Group and KalVista announced on 29 Apr 2026 a definitive agreement for Chiesi to acquire KalVista for $27.00 per share in cash, implying approximately $1.9bn of equity consideration, with closing expected in Q3 2026. (Business Wire)

Independent reports confirm the price, timing, and strategic rationale, with Reuters noting this would be the largest acquisition in Chiesi’s history and that Chiesi expects to fund the deal with cash and debt. (Reuters, Fierce Pharma)

60-second thesis frame

The diligence hinge is whether Chiesi is buying a durable rare-disease access platform or overpaying for a strong early launch in a narrow, increasingly competitive HAE category. EKTERLY, sebetralstat, is the first oral on-demand plasma kallikrein inhibitor for HAE attacks and is approved in the US, EU, UK, Switzerland, Australia, Singapore, and Japan for patients aged 12 and older. (Business Wire, accessdata.fda.gov, ema.europa.eu) Confidence rises if Chiesi can preserve US launch momentum, expand pediatric and international access, and defend premium rare-disease economics; it falls if payer controls, injectable incumbents, or next-wave competitors compress adoption before the asset scales.

The seven diligence questions

Clinical

• Does oral convenience translate into earlier treatment, fewer severe attacks, and measurable real-world outcome gains versus injectable on-demand options, not just faster symptom relief versus placebo in KONFIDENT? (NEJM KONFIDENT publication, ClinicalTrials.gov NCT05259917)

• How strong is the safety and pharmacokinetic case for expansion into children aged 2–11, and what residual risk remains around CYP3A4 interactions, hepatic impairment, pregnancy, and severe laryngeal attacks? (FDA label, KONFIDENT-KID NCT06467084)

Payer or Access

• Will US payers treat EKTERLY as a differentiated oral option, or as a high-cost alternative that must step through lower-cost injectable comparators?

• In the UK, can KalVista and Chiesi overcome NICE’s draft non-recommendation, which cited uncertainty in indirect comparisons and evidence versus Berinert, Cinryze, or icatibant? (NICE draft guidance)

Ops or Adoption

Can Chiesi scale US rare-immunology commercial infrastructure without disrupting KalVista’s early launch, which generated $49m in 2025 sales after US launch in July 2025? (Business Wire)

Competitive

• How much share can EKTERLY take from established acute therapies, and how defensible is the oral on-demand position as HAE investment interest rises around Pharvaris and other kallikrein or bradykinin-pathway approaches? (Investors)

Team or Cap table

• Does the $27.00 all-cash tender offer secure enough shareholder support, and are there any timing, antitrust, or competing-bid risks before the expected Q3 2026 close? (SEC , Business Wire)

Red flags

• Payer pushback becomes visible in prior authorization, step edits, or HTA outcomes, especially if NICE’s draft position hardens into final access friction. (NICE draft guidance)

• Real-world uptake plateaus after early adopters, showing that oral convenience does not materially expand treated attacks or switch behavior from injectable acute therapies.

• Pediatric expansion, international approvals, or tender-offer closing timelines slip, weakening the strategic case that Chiesi is buying a global rare-disease growth asset rather than a US launch asset. (SEC)

Next catalyst

Tender-offer materials on Schedule TO and KalVista’s Schedule 14D-9 should be filed with the SEC after the offer commences, with transaction close targeted for Q3 2026 subject to majority tender, regulatory approvals, and other customary conditions. (Business Wire, SEC)

FAQ

What exactly changed by Chiesi Group’s “Chiesi Group to Acquire KalVista Pharmaceuticals” announcement on 29 Apr 2026, and why does it matter for hereditary angioedema?

Chiesi agreed to acquire KalVista for $27.00 per share in cash, or approximately $1.9bn of equity consideration, adding EKTERLY, sebetralstat, to its rare-immunology portfolio. ([Chiesi Group to Acquire KalVista Pharmaceuticals] ) The deal matters because EKTERLY is positioned as the first oral on-demand therapy for HAE attacks, potentially changing treatment behavior in a market historically served by injectable or infused options. (FDA approval package)

What is the regulatory status after Chiesi Group’s 29 Apr 2026 KalVista acquisition announcement in the US, UK, and EU?

In the US, the FDA approved EKTERLY on 3 Jul 2025 for acute HAE attacks in adults and pediatric patients aged 12 years and older. (FDA approval package) In the EU, EMA says Ekterly received marketing authorisation valid throughout the EU on 17 Sep 2025. (EMA Ekterly EPAR) In the UK, MHRA issued an Early Access to Medicines Scheme scientific opinion in March 2025 for sebetralstat in HAE attacks in adults and adolescents aged 12 and older. (MHRA EAMS scientific opinion).

Which endpoints in KONFIDENT supported the asset behind Chiesi Group’s 29 Apr 2026 KalVista acquisition announcement?

The Phase 3 KONFIDENT trial evaluated sebetralstat for on-demand treatment of HAE attacks, and NEJM reported faster times to beginning of symptom relief, reduction in attack severity, and complete attack resolution versus placebo. (NEJM KONFIDENT publication) ClinicalTrials.gov identifies the pivotal study as NCT05259917, a Phase 3 crossover trial in adolescent and adult patients. (ClinicalTrials.gov NCT05259917)

What safety issues matter after Chiesi Group’s 29 Apr 2026 KalVista acquisition announcement, and could they affect use?

The FDA label highlights CYP3A4 interaction considerations, dose adjustment with moderate CYP3A4 inhibitors, avoidance with strong CYP3A4 inhibitors, and cautions in hepatic impairment. (FDA label) These issues are manageable in specialist rare-disease care, but they matter for broad real-world prescribing because HAE patients may need rapid self-treatment during attacks.

How could payers and HTA bodies shape access after Chiesi Group’s 29 Apr 2026 KalVista acquisition announcement?

US access will depend on whether payers view oral on-demand treatment as a differentiated route and adherence benefit, or require step edits against established on-demand therapies. In the UK, NICE draft guidance said sebetralstat should not be used to treat HAE attacks in people 12 years and over, citing uncertainty versus relevant comparators, so final HTA resolution is a key access risk. (NICE draft guidance)

Publisher / Disclosure

Publisher: LucidQuest Ventures Ltd. Produced: 30 Apr 2026, 08:49 London. Purpose: general and impersonal information. Not investment research or advice, no offer or solicitation, no suitability assessment. UK: directed at investment professionals under Article 19(5) and certain high-net-worth entities under Article 49(2)(a)–(d) of the Financial Promotion Order 2005. Others should not act on this. Sources and accuracy: public sources believed reliable, provided “as is,” may change without notice. No duty to update. Past performance is not reliable. Forward-looking statements carry risks. Methodology: questions-first framework using public sources. No conflicts. Authors do not hold positions unless stated. © 2026 LucidQuest Ventures Ltd.

Entities / Keywords

Chiesi Group; KalVista Pharmaceuticals; EKTERLY; sebetralstat; hereditary angioedema; HAE; plasma kallikrein inhibitor; rare disease; rare immunology; Chiesi Global Rare Diseases; FDA; EMA; MHRA; NICE; SEC; Schedule TO; Schedule 14D-9; tender offer; $27 per share; $1.9bn; KONFIDENT; KONFIDENT-S; KONFIDENT-KID; NCT05259917; NCT05505916; NCT06467084; Berinert; Cinryze; icatibant; Ruconest; Pharvaris; BioCryst; Astria Therapeutics; US; EU; UK; Japan; Switzerland; Australia; Singapore; payer access; HTA; pediatric expansion

Find more Lucid Diligence Briefs here.